---
title: "Protagonist Therapeutics Leaps on Report of Possible J&J Deal"
description: "Shares of Protagonist Therapeutics rose 9.4% to $73.34 following a report from The Wall Street Journal that Johnson & Johnson is in talks to acquire the company. Protagonist has a market capitalizatio"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/260667559.md"
published_at: "2025-10-10T15:52:01.000Z"
---

# Protagonist Therapeutics Leaps on Report of Possible J&J Deal

> Shares of Protagonist Therapeutics rose 9.4% to $73.34 following a report from The Wall Street Journal that Johnson & Johnson is in talks to acquire the company. Protagonist has a market capitalization exceeding $4 billion based on its recent closing price of $67.04. However, the deal is not guaranteed, and specific details remain undisclosed.

By Colin Kellaher

Shares of Protagonist Therapeutics moved higher after The Wall Street Journal reported that Johnson & Johnson is in talks to buy company, citing people familiar with the matter.

Protagonist shares were recently up 9.4%, to $73.34.

A deal isn't guaranteed, and the details being discussed couldn't be learned, the people said, the Journal reported.

Protagonist sports a market capitalization topping $4 billion based on Thursday's closing price of $67.04 for the Newark, Calif., clinical-stage biopharmaceutical company.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

10-10-25 1147ET

### Related Stocks

- [JNJ.US - Johnson & Johnson](https://longbridge.com/en/quote/JNJ.US.md)
- [PTGX.US - Protagonist Therap](https://longbridge.com/en/quote/PTGX.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Key facts: J&J liable for cancer in talc case; $30M lawsuit filed against lenders | A Pennsylvania jury found Johnson & Johnson liable for cancer linked to its talc baby powder, awarding $250,000 to a pla | [Link](https://longbridge.com/en/news/275986663.md) |
| 5,056 Shares in Johnson & Johnson $JNJ Acquired by Uniting Wealth Partners LLC | Uniting Wealth Partners LLC acquired 5,056 shares of Johnson & Johnson (NYSE: JNJ) in Q3, valued at approximately $938,0 | [Link](https://longbridge.com/en/news/276006840.md) |
| Protagonist Therapeutics (PTGX) to Release Earnings on Friday | Protagonist Therapeutics (NASDAQ:PTGX) is set to release its Q4 2025 earnings on February 20, with analysts expecting a  | [Link](https://longbridge.com/en/news/275855554.md) |
| Pennsylvania jury finds Johnson & Johnson liable for cancer in latest talc trial | A Pennsylvania jury awarded $250,000 to the family of Gayle Emerson, who claimed Johnson & Johnson's talc-based baby pow | [Link](https://longbridge.com/en/news/275939086.md) |
| Assenagon Asset Management S.A. Decreases Stock Holdings in Protagonist Therapeutics, Inc. $PTGX | Assenagon Asset Management S.A. reduced its stake in Protagonist Therapeutics, Inc. by 28.4% in Q3, owning 65,756 shares | [Link](https://longbridge.com/en/news/270461220.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.